Exciting Treatment Advances in Upper Tract Urothelial Cancer: Seth P. Lerner, MD, FACS

Substantial developments are under way in the treatment of upper tract urothelial cancer (UTUC). Seth P. Lerner, MD, FACS, recently spoke with i3 Health about mitomycin gel (JelmytoTM, UroGen Pharma), now FDA approved as the first agent specifically indicated for the treatment of low-grade UTUC. In this second installment of his interview, Dr. Lerner, principal investigator of the OLYMPUS study, on which the mitomycin gel approval was based, discusses research advances in the treatment of both l...
Continue reading

Tucatinib for HER2-Positive Metastatic Breast Cancer: Eric P. Winer, MD

In this interview with i3 Health, Eric P. Winer, MD, discusses tucatinib (TukysaTM, Seattle Genetics), recently approved by the FDA in combination with trastuzumab and capecitabine for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer previously treated with at least one anti-HER2­–based regimen in the metastatic setting. Dr. Winer, principal investigator of the phase 3 HER2CLIMB trial, on which the approval was based, discusses tucat...
Continue reading

Ripretinib Approved: Advanced Gastrointestinal Stromal Tumor

The FDA has approved ripretinib (QinlockTM, Deciphera Pharmaceuticals, LLC) for adults with metastatic gastrointestinal stromal tumor (GIST) previously treated with at least three kinase inhibitors, including imatinib.Gastrointestinal stromal tumor is a rare tumor type with a yearly incidence of around 4,000 to 6,000 in the United States."Despite the progress that has been made over the past 20 years in developing treatments for GIST, including four FDA-approved targeted therapies––imatinib in 2...
Continue reading

Kaposi Sarcoma: Pomalidomide Granted Accelerated Approval

In the first new drug approval for Kaposi sarcoma in over 20 years, the FDA has expanded the indication for pomalidomide (Pomalyst®, Celgene) in an accelerated approval, both for HIV-negative patients with Kaposi sarcoma and for patients with AIDS-related Kaposi sarcoma resistant to highly active antiretroviral therapy (HAART).The approval was based on data from Study 12-C-0047 (NCT01495598), an open-label, single-arm phase 1/2 trial in which 28 patients with Kaposi sarcoma, including 18 who wer...
Continue reading

Pyrotinib/Capecitabine Effective for HER2-Positive Metastatic Breast Cancer

Pyrotinib, an irreversible pan-ErbB inhibitor, provides an effective treatment option in combination with capecitabine for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, according to results of a phase 3 trial to be presented later this month in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.The open-label, multicenter PHOEBE trial enrolled patients with HER2-positive metastatic breast cancer following treatment ...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.